Market Cap 179.83B
Revenue (ttm) 33.42B
Net Income (ttm) 4.09B
EPS (ttm) N/A
PE Ratio 15.16
Forward PE 15.58
Profit Margin 12.24%
Debt to Equity Ratio 5.67
Volume 833,600
Avg Vol 2,849,552
Day's Range N/A - N/A
Shares Out 538.48M
Stochastic %K 98%
Beta 0.45
Analysts Sell
Price Target $328.04

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 805 447 1000
Fax: 805 447 1010
Address:
One Amgen Center Drive, Thousand Oaks, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:24 PM
Actionable Trade Alert for $AMGN: Market Context: Currently, $AMGN is trading at $333.96, showing a neutral RSI at 43.93, indicating potential for upward movement as it is below the 50 threshold. The stock is above the 30-day MA of 332.66 and significantly above the 50-day MA of 320.66, suggesting a bullish trend in the short term. Directional Bias: The recent 60-day high of 346.38 indicates resistance, while the low of 283.0 shows a solid support level. Given the current price action and the RSI, we anticipate a bullish reversal. Trade Plan: - Suggested Entry: $335.00 - Stop Loss: $325.00 (risking $10.00) - Take Profit Targets: 1. $345.00 (Target 1: 2.98% ROI) 2. $355.00 (Target 2: 5.96% ROI) 3. $390.00 (Target 3: 16.73% ROI) This plan provides a risk-reward ratio that aligns with our target of at least 17% ROI on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 25 at 6:00 AM
$AMGN takes bold steps with a landmark deal to lower U.S. drug prices! 💊 🔹 Partnered with the Trump administration to align drug prices with international levels. 🔹 AMGN plans $2.5B investment in domestic manufacturing, enhancing U.S. production and research capabilities. Discover the full impact on pharma here 👉 https://www.zacks.com/stock/news/2808682/amgen-strikes-drug-pricing-deal-with-trump-what-investors-should-know?cid=sm-stocktwits-2-2808682-body-26188&ADID=SYND_STOCKTWITS_TWEET_2_2808682_BODY_26188
0 · Reply
Alexisvan
Alexisvan Dec. 24 at 4:46 PM
0 · Reply
Alexisvan
Alexisvan Dec. 24 at 4:46 PM
$QCOM $HDB $GEV $SCHW $AMGN Great news.
0 · Reply
EndBossEquity
EndBossEquity Dec. 24 at 3:44 PM
$AMGN The next inflection point emerges from the pace at which operating leverage materializes relative to expectations, with outcomes shaped by timing and discipline. Outcomes hinge on delivery, not scale.
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Dec. 24 at 3:42 PM
$KYTX all big players in the cell therapy space like $AZN $GILD $AMGN $VRTX will have noticed these life changing results and have their M&A analysts running the numbers up and down right now to evaluate next steps in 2026. A merry Christmas to everyone here. Let's do some good with our investments here on this holy day 🎄🎅💲 https://kyvernatx.com/education-events/educational-videos/
1 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 3:34 PM
$AMGN takes bold steps with a landmark deal to lower U.S. drug prices! 💊 🔹 Partnered with the Trump administration to align drug prices with international levels. 🔹 AMGN plans $2.5B investment in domestic manufacturing, enhancing U.S. production and research capabilities. Discover the full impact on pharma here 👉 https://www.zacks.com/stock/news/2808682/amgen-strikes-drug-pricing-deal-with-trump-what-investors-should-know?cid=sm-stocktwits-2-2808682-body-26188&ADID=SYND_STOCKTWITS_TWEET_2_2808682_BODY_26188
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 2:34 PM
$AMGN just struck a rare Washington win — and investors should pay attention. The company signed a pricing deal with the Trump administration that cuts U.S. drug costs, expands direct-to-consumer access, and secures tariff relief tied to domestic investment — a multi-angle policy tailwind rolled into one. ⚠️➡️📈 See how this deal reshapes the risk/reward here 👉 https://www.zacks.com/stock/news/2808682/amgen-strikes-drug-pricing-deal-with-trump-what-investors-should-know?cid=sm-stocktwits-2-2808682-teaser-26187&ADID=SYND_STOCKTWITS_TWEET_2_2808682_TEASER_26187
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 6:00 AM
Novo Nordisk vs. Amgen: Which stock is the smarter play? $NVO stock has plunged 32% in six months amid headwinds like competition from Eli Lilly and compounded semaglutide alternatives. Meanwhile, $AMGN has gained 19.6%, supported by a diverse portfolio and upward-trending EPS estimates. Discover why Amgen may be the better choice now 👉 https://www.zacks.com/stock/news/2808025/novo-nordisk-vs-amgen-which-healthcare-stock-is-the-smarter-choice?cid=sm-stocktwits-2-2808025-body-25998&ADID=SYND_STOCKTWITS_TWEET_2_2808025_BODY_25998
0 · Reply
emeraldbayrider
emeraldbayrider Dec. 24 at 2:23 AM
$AMGN $LLY $NVO Surprised NVO was meh today, but expect it to lift well in the days and weeks ahead. Today dbag Cramer said LLY weight loss on oral version is better than NVO version, but the opposite is what the clinical data shows. 16.6% weight loss on the NVO! Then there is this: https://x.com/SixSigmaCapital/status/2003447827867820409?s=20
2 · Reply
Latest News on AMGN
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND

Dec 9, 2025, 4:01 PM EST - 16 days ago

AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND


Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 27 days ago

Dogs Of The Dow Continue Outperforming Broader Market

DIA JNJ MAGS SPY


AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE

Nov 24, 2025, 4:10 PM EST - 4 weeks ago

AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE


Trade Tracker: Bill Baruch buys more Amgen

Nov 13, 2025, 1:54 PM EST - 6 weeks ago

Trade Tracker: Bill Baruch buys more Amgen


Cramer's Stop Trading: Amgen

Nov 13, 2025, 10:30 AM EST - 6 weeks ago

Cramer's Stop Trading: Amgen


Amgen CEO talks trial results of cardiac drug Repatha

Nov 10, 2025, 7:40 PM EST - 6 weeks ago

Amgen CEO talks trial results of cardiac drug Repatha


Amgen cholesterol drug cuts risk of first cardiac event by 25%

Nov 8, 2025, 10:11 AM EST - 6 weeks ago

Amgen cholesterol drug cuts risk of first cardiac event by 25%


Amgen: Buy This Cheap Biotech Leader

Nov 8, 2025, 12:11 AM EST - 6 weeks ago

Amgen: Buy This Cheap Biotech Leader


Stock Of The Day: Will Amgen Reverse Again?

Nov 6, 2025, 10:41 AM EST - 7 weeks ago

Stock Of The Day: Will Amgen Reverse Again?


Amgen: Q3 Earnings Indicate Strong Emphasis On R&D

Nov 5, 2025, 12:40 PM EST - 7 weeks ago

Amgen: Q3 Earnings Indicate Strong Emphasis On R&D


Amgen Inc. (AMGN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:36 PM EST - 7 weeks ago

Amgen Inc. (AMGN) Q3 2025 Earnings Call Transcript


AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Nov 4, 2025, 4:01 PM EST - 7 weeks ago

AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS


AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND

Oct 31, 2025, 4:01 PM EDT - 7 weeks ago

AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND


AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS

Oct 29, 2025, 4:01 PM EDT - 2 months ago

AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS


Cramer's Stop Trading - Amgen

Oct 3, 2025, 10:22 AM EDT - 3 months ago

Cramer's Stop Trading - Amgen


Amgen Shares Cross Above 200 DMA

Oct 1, 2025, 11:35 AM EDT - 3 months ago

Amgen Shares Cross Above 200 DMA


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:24 PM
Actionable Trade Alert for $AMGN: Market Context: Currently, $AMGN is trading at $333.96, showing a neutral RSI at 43.93, indicating potential for upward movement as it is below the 50 threshold. The stock is above the 30-day MA of 332.66 and significantly above the 50-day MA of 320.66, suggesting a bullish trend in the short term. Directional Bias: The recent 60-day high of 346.38 indicates resistance, while the low of 283.0 shows a solid support level. Given the current price action and the RSI, we anticipate a bullish reversal. Trade Plan: - Suggested Entry: $335.00 - Stop Loss: $325.00 (risking $10.00) - Take Profit Targets: 1. $345.00 (Target 1: 2.98% ROI) 2. $355.00 (Target 2: 5.96% ROI) 3. $390.00 (Target 3: 16.73% ROI) This plan provides a risk-reward ratio that aligns with our target of at least 17% ROI on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 25 at 6:00 AM
$AMGN takes bold steps with a landmark deal to lower U.S. drug prices! 💊 🔹 Partnered with the Trump administration to align drug prices with international levels. 🔹 AMGN plans $2.5B investment in domestic manufacturing, enhancing U.S. production and research capabilities. Discover the full impact on pharma here 👉 https://www.zacks.com/stock/news/2808682/amgen-strikes-drug-pricing-deal-with-trump-what-investors-should-know?cid=sm-stocktwits-2-2808682-body-26188&ADID=SYND_STOCKTWITS_TWEET_2_2808682_BODY_26188
0 · Reply
Alexisvan
Alexisvan Dec. 24 at 4:46 PM
0 · Reply
Alexisvan
Alexisvan Dec. 24 at 4:46 PM
$QCOM $HDB $GEV $SCHW $AMGN Great news.
0 · Reply
EndBossEquity
EndBossEquity Dec. 24 at 3:44 PM
$AMGN The next inflection point emerges from the pace at which operating leverage materializes relative to expectations, with outcomes shaped by timing and discipline. Outcomes hinge on delivery, not scale.
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Dec. 24 at 3:42 PM
$KYTX all big players in the cell therapy space like $AZN $GILD $AMGN $VRTX will have noticed these life changing results and have their M&A analysts running the numbers up and down right now to evaluate next steps in 2026. A merry Christmas to everyone here. Let's do some good with our investments here on this holy day 🎄🎅💲 https://kyvernatx.com/education-events/educational-videos/
1 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 3:34 PM
$AMGN takes bold steps with a landmark deal to lower U.S. drug prices! 💊 🔹 Partnered with the Trump administration to align drug prices with international levels. 🔹 AMGN plans $2.5B investment in domestic manufacturing, enhancing U.S. production and research capabilities. Discover the full impact on pharma here 👉 https://www.zacks.com/stock/news/2808682/amgen-strikes-drug-pricing-deal-with-trump-what-investors-should-know?cid=sm-stocktwits-2-2808682-body-26188&ADID=SYND_STOCKTWITS_TWEET_2_2808682_BODY_26188
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 2:34 PM
$AMGN just struck a rare Washington win — and investors should pay attention. The company signed a pricing deal with the Trump administration that cuts U.S. drug costs, expands direct-to-consumer access, and secures tariff relief tied to domestic investment — a multi-angle policy tailwind rolled into one. ⚠️➡️📈 See how this deal reshapes the risk/reward here 👉 https://www.zacks.com/stock/news/2808682/amgen-strikes-drug-pricing-deal-with-trump-what-investors-should-know?cid=sm-stocktwits-2-2808682-teaser-26187&ADID=SYND_STOCKTWITS_TWEET_2_2808682_TEASER_26187
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 6:00 AM
Novo Nordisk vs. Amgen: Which stock is the smarter play? $NVO stock has plunged 32% in six months amid headwinds like competition from Eli Lilly and compounded semaglutide alternatives. Meanwhile, $AMGN has gained 19.6%, supported by a diverse portfolio and upward-trending EPS estimates. Discover why Amgen may be the better choice now 👉 https://www.zacks.com/stock/news/2808025/novo-nordisk-vs-amgen-which-healthcare-stock-is-the-smarter-choice?cid=sm-stocktwits-2-2808025-body-25998&ADID=SYND_STOCKTWITS_TWEET_2_2808025_BODY_25998
0 · Reply
emeraldbayrider
emeraldbayrider Dec. 24 at 2:23 AM
$AMGN $LLY $NVO Surprised NVO was meh today, but expect it to lift well in the days and weeks ahead. Today dbag Cramer said LLY weight loss on oral version is better than NVO version, but the opposite is what the clinical data shows. 16.6% weight loss on the NVO! Then there is this: https://x.com/SixSigmaCapital/status/2003447827867820409?s=20
2 · Reply
judgeyoung2
judgeyoung2 Dec. 23 at 7:12 PM
$AMGN so maritide pt 2 was supposed to readout before year end. now they say “expect to provide an update in the new year.” should we take this to mean january?
0 · Reply
CoyoteUgly
CoyoteUgly Dec. 23 at 3:44 PM
0 · Reply
gata2016
gata2016 Dec. 23 at 2:52 PM
$KYTX Another solid day on our way back to 10. Nice $AMGN
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 23 at 2:48 PM
🎯 Target Hit 🏁 📨 From Dec 15, 2025 🏛️ $AMGN 💵 Entry: $325.3000 ✅ Exit: $332.9446 💰 P/L: +2.35% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Quantumup
Quantumup Dec. 23 at 2:43 PM
Truist reiterated $VRDN Buy-$41, and said: 'Veli's Priority Review & June 30 PDUFA Set, Confirming Clean, Catalyst-Rich 2026 Set-Up' $AMGN $IMVT NVS ARGX Truist added: This morning's BLA acceptance and priority review for Veli' comes in as expected, though reinforcing of the solid and still-underappreciated execution and opportunity available for VRDN and shares give the clean and attractive set-up across the portfolio; a June 30 PDUFA with robust launch preparations underway open the door to a mid-2026 launch - our base case - and VRDN's foray into TED. On the path for pivotal SC data in early 2026, a mid-year IV PDUFA, and potential launch later this year, we like the multi-pronged but direct-course appreciation potential on VRDN shares and reiterate our Buy rating and $41 price target.
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 2:17 PM
$NVO vs. $AMGN — which healthcare giant actually wins this matchup? GLP-1 leadership, pipeline depth, and diversification are at the center of this head-to-head, setting up a compelling comparison between two heavyweight healthcare stocks. Find out which stock comes out on top 👉 https://www.zacks.com/stock/news/2808025/novo-nordisk-vs-amgen-which-healthcare-stock-is-the-smarter-choice?cid=sm-stocktwits-2-2808025-teaser-25962&ADID=SYND_STOCKTWITS_TWEET_2_2808025_TEASER_25962
0 · Reply
albiegf13
albiegf13 Dec. 23 at 1:46 PM
0 · Reply
emeraldbayrider
emeraldbayrider Dec. 23 at 12:57 AM
$NVO $AMGN $LLY Have you ever noticed when a stock jumps on a discernable catalyst manifesting itself after hours... that there is more ofter than not a big continuation of the jump during the next day's opening as the serious 13F longs add/pull hedges and the rapidly buried pro shorts aggressively move to cover? just a hunch, but imo shorts are f'd here come tomorrow!
0 · Reply
emeraldbayrider
emeraldbayrider Dec. 23 at 12:42 AM
$NVO Other than $AMGN, a name I have made several million on over since my first serious allocation in 1985 (check out that long term monthly chart!), I tend to avoid the biotech and pharma names. However, this stock has been thrashed hard to wtf oversold, and now the key catalyst just hit the newswire. Watch this rip when the Danish market opens, and roar past the 200dma ($60.68) in the days ahead -- perhaps even opening above that tomorrow. Not only are they first to earn FDA approval and therefore distribution and insurance qualifications with an oral version, it has better clinical efficacy than $LLY version -- so it is bound to become the runaway name for weeks to come. Pure spec for me obviously... but love the risk reward on it tonight, and I always enjoy unhedged shorts getting their gnads kicked in!
0 · Reply
notreload_ai
notreload_ai Dec. 22 at 9:38 PM
$AMRX , $AMGN ... Amneal Pharmaceuticals and mAbxience announce FDA approval of Boncresa and Oziltus, biosimilar alternatives to Prolia and XGEVA for bone health treatment. https://notreload.xyz/fda-approves-amneals-denosumab-biosimilars-for-bone-health/
0 · Reply
albiegf13
albiegf13 Dec. 22 at 8:36 PM
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Dec. 22 at 1:59 PM
$ARWR Named Top Pick at Piper 2026 $ABBV $AMGN $TEVA
0 · Reply